T0 Baseline (pre-randomisation) | T1 follow-up (~ week 6) | T2 follow-up primary endpoint (~ week 20) | |
---|---|---|---|
Demographics | * | ||
Diagnosis (stroke or TIA) | * | ||
Past history of anxiety or depression | * | ||
Medications for anxiety or mood | * | ||
mRS | * | * | * |
EQ5D5L-VAS | * | * | * |
GAD-7 | * | * | * |
PHQ-2 | * | * | * |
Modified FQ | * | * | * |
Single question on concurrent treatment for mood or anxiety (drug or non-drug) | * | * | * |
User feedback survey | * | ||
Sub study of wearing a smartwatch | |||
Smartwatch for measuring rest/activity | Continuous monitoring throughout the trial from T0 to T2 |